A detailed history of High Tower Advisors, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 16,215 shares of ALKS stock, worth $435,534. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,215
Previous 18,538 12.53%
Holding current value
$435,534
Previous $501,000 22.16%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$23.21 - $27.24 $53,916 - $63,278
-2,323 Reduced 12.53%
16,215 $390,000
Q1 2024

May 06, 2024

BUY
$26.4 - $32.56 $489,403 - $603,597
18,538 New
18,538 $501,000
Q4 2021

Feb 10, 2022

SELL
$21.47 - $32.08 $653,160 - $975,937
-30,422 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$23.37 - $32.13 $23,556 - $32,387
1,008 Added 3.43%
30,422 $934,000
Q2 2021

Aug 06, 2021

BUY
$18.78 - $25.15 $552,394 - $739,762
29,414 New
29,414 $717,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.41B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.